FDA
-
-
-
-
-
-
-
Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic Fibrosis
-
-
-
-
-
-
-
Pre-Open Movers 12/11: (PTI) (OLLI) (PLAB) Higher (ITRM) (GME) (PLCE) Lower (more...)
-
-
-
-
-
-
-
Proteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis Conference
-
-
-
-
-
-
-
Proteostasis Therapeutics Announces Management Changes and Appointments
-
-
-
-
-
-
-
Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients
-
-
-
-
-
-
-
Proteostasis Therapeutics to Present at the Cantor Global Healthcare Conference
-
-
-
-
-
-
-
UPDATE: Proteostasis Therapeutics (PTI) Secures Endorsement from Therapeutic Development Network for Phase 2 Study to Investigate PTI-428 in CF Patients
-
322,093 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

